Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), headquartered in California, is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing next-generation therapeutics for diseases representing significant unmet medical needs and societal and patient burdens, as well as their families. Reviva's current pipeline focuses on central nervous system, respiratory, and metabolic disorders. Reviva employs a chemogenomics-driven technology platform and proprietary chemistry to develop novel drugs. Reviva’s pipeline currently includes two drug candidates, RP5063 (Brilaroxazine) and RP1208, both internally discovered new chemical entities. Reviva has been granted composition-of-matter patents for RP5063 and RP1208 in the United States (US), Europe, and several other countries.